Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
481-500 of 1,738 trials

Cervical Cancer: Fertility-Sparing Treatment Study

We are studying a new approach for women with early-stage cervical cancer to see if chemotherapy followed by surgery can help preserve fertility. This trial aims to evaluate the safety and effectiveness of this treatment method.

Cervical Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Immunoglobulin A Nephropathy: Sibeprenlimab Study

We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.

IgA Nephropathy>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNephrology

Hemophilia B: REGV131-LNP1265 Gene Therapy

We are studying a new gene therapy to see if it is safe and helps adults with Hemophilia B produce a vital clotting factor. The trial will also assess how it affects bleeding events.

Hemophilia B>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Advanced Solid Tumors: AZD8421 Study

We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.

ER+ HER2- Advanced Breast CancerHigh-Grade Serous Ovarian Cancer (HGSOC)Safety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

HER2-Positive Breast Cancer: Trastuzumab and Pertuzumab Study

We are exploring a new treatment approach for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. This study aims to see how well this treatment works and its safety compared to existing options.

HER2-positive Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

ACP-204 for Alzheimer's Disease Psychosis

We are testing the effects of ACP-204 in adults with Alzheimer's disease psychosis to see if it helps improve symptoms compared to a placebo.

Alzheimer's DiseaseAlzheimer's Disease Psychosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Dupuytren's Contracture: Bacterial Collagenase Treatment

We are studying a new bacterial collagenase injection for patients with Dupuytren's contracture to see if it improves hand function and reduces contracture compared to a placebo.

Dupuytren's Contracture6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology

Generalized Myasthenia Gravis: Efgartigimod Safety Study

We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.

Myasthenia GravisEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Long-Term Safety Study of NTLA-2001

We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.

Hereditary Amyloidosis>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Thalassemia and Myelodysplastic Syndromes: SP-420 Treatment Study

We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.

Thalassemia and Myelodysplastic Syndromes6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Zolpidem Responses: Understanding Effects in Different Patients

We are investigating how zolpidem affects people with disorders of consciousness, vision impairments, and healthy volunteers. This study aims to uncover why some individuals respond differently to the medication.

Vision ImpairmentsDisorders of ConsciousnessHealthy Volunteers≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurologyPsychiatry

Advanced Solid Tumors: TAPISTRY Immuno-Oncology Study

We are testing a new treatment for patients with advanced or metastatic solid tumors that have specific genetic changes. The goal is to see how well it works and how it affects patients' daily lives.

Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Oral Vancomycin for Primary Sclerosing Cholangitis

We are studying whether oral vancomycin can improve liver health in adults and young patients with Primary Sclerosing Cholangitis. The trial will also look at the safety of the treatment and its effects on related health conditions.

Primary Sclerosing Cholangitis3-6 monthsEfficacy phase (II)Standard MedicinesGastroenterologyHepatology

Breast Cancer Surgery: Ketorolac and Pregabalin Study

We are exploring how preoperative use of ketorolac and pregabalin affects inflammation and pain in breast cancer patients. This study looks at how these effects may vary based on body weight.

Estrogen Receptor Positive Breast Cancer≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Vitiligo Treatment: Targeting TYK2 Responses

We are exploring a new treatment aimed at improving skin color in people with vitiligo. This study will help us understand if targeting specific responses can be beneficial.

Vitiligo>2 yearsEfficacy phase (II)Dermatology

Urothelial Cancer: Nivolumab with Relatlimab

We are studying a combination of nivolumab and relatlimab as a pre-surgery treatment for muscle-invasive bladder cancer. The goal is to see if this approach is effective and safe compared to nivolumab alone.

Muscle-Invasive Bladder CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyUrology

Heart Blood Flow Measurement: SYN2 PET Imaging

We are testing a new imaging method to measure blood flow in the heart for patients suspected of having coronary artery disease. The study aims to ensure this method is accurate and safe for use.

Coronary Artery Disease1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Advanced Solid Tumors: MDNA11 and Pembrolizumab Study

We are investigating the safety and effectiveness of MDNA11, given alone or with pembrolizumab, in patients with advanced solid tumors. This study aims to find the best dose and understand how the treatment works.

Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Myasthenia Gravis: NMD670 Treatment Study

We are testing different doses of NMD670 in adults with Myasthenia Gravis to see if it improves muscle strength. This study will help us understand how effective the treatment is compared to a placebo.

Myasthenia Gravis≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Multiple Sclerosis: Disodium Cromoglycate Treatment

We are studying whether oral disodium cromoglycate can help reduce fatigue and urinary problems in people with multiple sclerosis. The trial will also assess its safety and impact on quality of life.

Multiple SclerosisEfficacy phase (II)Standard MedicinesInternal MedicineNeurology